다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd (ROIV) 뉴스

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ROIV

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/03	21:00	GlobeNewswire Inc.	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	NASDAQ:ROIV	Roivant Sciences Ltd
2024/12/03	21:00	GlobeNewswire Inc.	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis	NASDAQ:ROIV	Roivant Sciences Ltd
2024/11/12	21:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/10/30	05:35	GlobeNewswire Inc.	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2024/10/28	22:25	GlobeNewswire Inc.	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NASDAQ:ROIV	Roivant Sciences Ltd
2024/09/18	20:30	GlobeNewswire Inc.	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NASDAQ:ROIV	Roivant Sciences Ltd
2024/09/10	19:30	GlobeNewswire Inc.	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator	NASDAQ:ROIV	Roivant Sciences Ltd
2024/09/10	19:30	GlobeNewswire Inc.	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress	NASDAQ:ROIV	Roivant Sciences Ltd
2024/09/09	20:00	GlobeNewswire Inc.	Roivant Provides Update on Graves’ Disease Development Program	NASDAQ:ROIV	Roivant Sciences Ltd
2024/08/08	20:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/07/26	05:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/31	10:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/31	05:46	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/30	20:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/23	10:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ROIV	Roivant Sciences Ltd
2024/05/17	05:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2024/04/02	20:00	GlobeNewswire Inc.	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	NASDAQ:ROIV	Roivant Sciences Ltd
2024/03/27	07:22	PR Newswire (US)	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600	NASDAQ:ROIV	Roivant Sciences Ltd
2024/02/13	21:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2024/01/31	06:05	GlobeNewswire Inc.	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	NASDAQ:ROIV	Roivant Sciences Ltd
2023/12/21	06:30	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:ROIV	Roivant Sciences Ltd
2023/12/14	23:00	GlobeNewswire Inc.	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/28	21:00	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/27	22:00	GlobeNewswire Inc.	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/13	21:00	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	NASDAQ:ROIV	Roivant Sciences Ltd
2023/11/10	22:00	GlobeNewswire Inc.	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	NASDAQ:ROIV	Roivant Sciences Ltd

검색 관련기사 보기:NASDAQ:ROIV

1 2 3 4 5 다음 >>

US Dollar vs Sterling

Energy Select Sector SPDR

Health Care Select Sector

Deutsche Telekom (QX)

BNP Paribas (QX)

American Express

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관